PT  - JOURNAL ARTICLE
AU  - Judy R. van Beijnum
AU  - Patrycja Nowak-Sliwinska
AU  - Elisabeth J. M. Huijbers
AU  - Victor L. Thijssen
AU  - Arjan W. Griffioen
ED  - Rosenblum, Michael G.
TI  - The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
AID  - 10.1124/pr.114.010215
DP  - 2015 Apr 01
TA  - Pharmacological Reviews
PG  - 441--461
VI  - 67
IP  - 2
4099  - http://pharmrev.aspetjournals.org/content/67/2/441.short
4100  - http://pharmrev.aspetjournals.org/content/67/2/441.full
SO  - Pharmacol Rev2015 Apr 01; 67
AB  - The concept of antiangiogenic therapy in cancer treatment has led to the approval of different agents, most of them targeting the well known vascular endothelial growth factor pathway. Despite promising results in preclinical studies, the efficacy of antiangiogenic therapy in the clinical setting remains limited. Recently, awareness has emerged on resistance to antiangiogenic therapies. It has become apparent that the intricate complex interplay between tumors and stromal cells, including endothelial cells and associated mural cells, allows for escape mechanisms to arise that counteract the effects of these targeted therapeutics. Here, we review and discuss known and novel mechanisms that contribute to resistance against antiangiogenic therapy and provide an outlook to possible improvements in therapeutic approaches.